Drug Trial Radar · NCT00632645
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Last checked: Nov 20, 2026Latest source record: Jan 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Apr 2009
Primary completion
Apr 28, 2017
Study completion Apr 28, 2017
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 11, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade. The disease progression is classically characterized by a cognitive deterioration (cortical-frontal dementia), motor disorders (associating chorea, dystonia and bradykinesia), psychiatric disturbances (combining depression and irritability) and metabolic disorder (cachexia). The disease is fatal within 15 to 20 years in most patients. HD has no cure. Neuroleptics are the main drug used and the only to demonstrate its efficacy on chorea in clinical trials. But neuroleptics have also beneficial and adverse effects on other disease characteristics (motor, psychiatric, cognitive or metabolic). Their profile between beneficial and adverse effects could be different according the neuroleptics and their classification. The aim of this study is to compare beneficial and adverse effects of 3 different neuroleptics in HD.
Conditions
- Huntington Disease
Interventions
OlanzapineDrug
Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
XenazineDrug
Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
TiapridalDrug
Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- the Independence scaleTime frame: at 12 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Henri Mondor
Créteil, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.